FDA Weighs Approval Of A Lucrative Alzheimer's Drug, But Benefits Are Iffy
The agency is to decide byMonday whether to greenlight Biogen’s drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November.
Source: usf.edu